McKesson (NYSE:MCK) Stock Price Target Raised at Leerink Partners

McKesson (NYSE:MCK) had its price target hoisted by Leerink Partners from $1,070.00 to $1,200.00 in a report released on Thursday,Benzinga reports. Leerink Partners currently has an outperform rating on the stock.

MCK has been the topic of a number of other research reports. Evercore reiterated an “outperform” rating and issued a $950.00 target price (down from $1,000.00) on shares of McKesson in a research report on Thursday, August 6th. Robert W. Baird set a $1,015.00 price target on McKesson in a research report on Thursday, August 6th. Citigroup lifted their target price on shares of McKesson from $945.00 to $1,000.00 and gave the stock a “buy” rating in a research note on Friday, July 24th. Barclays upped their price objective on shares of McKesson from $925.00 to $1,000.00 and gave the company an “overweight” rating in a research note on Wednesday, August 19th. Finally, Morgan Stanley set a $977.00 price objective on McKesson in a report on Tuesday, October 6th. Fifteen equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $1,023.24.

McKesson Trading Up 0.6%

MCK stock opened at $1,075.38 on Thursday. The firm has a 50 day moving average of $934.72 and a 200-day moving average of $866.92. McKesson has a 12 month low of $723.68 and a 12 month high of $1,121.50. The firm has a market capitalization of $125.38 billion, a P/E ratio of 27.65, a price-to-earnings-growth ratio of 2.13 and a beta of 0.27.

McKesson (NYSE:MCK) last released its quarterly earnings results on Wednesday, November 4th. The company reported $11.68 earnings per share for the quarter, beating the consensus estimate of $10.72 by $0.96. The firm had revenue of $110.96 billion for the quarter, compared to analysts’ expectations of $109.90 billion. McKesson had a negative return on equity of 235.48% and a net margin of 1.12%. The company’s revenue was up 7.5% compared to the same quarter last year. During the same quarter last year, the firm posted $9.86 EPS. Sell-side analysts predict that McKesson will post 44.71 EPS for the current year.

McKesson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, January 4th. Shareholders of record on Tuesday, December 1st will be paid a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date is Tuesday, December 1st. McKesson’s dividend payout ratio (DPR) is currently 9.67%.

Insider Activity

In related news, EVP Francisco Fraga sold 600 shares of McKesson stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $1,050.00, for a total transaction of $630,000.00. Following the transaction, the executive vice president owned 5,064 shares in the company, valued at approximately $5,317,200. The trade was a 10.59% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Bradley E. Lerman sold 301 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $892.33, for a total value of $268,591.33. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 1,812 shares of company stock worth $1,794,182 over the last 90 days. 0.06% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. King Luther Capital Management Corp grew its stake in McKesson by 1.6% during the third quarter. King Luther Capital Management Corp now owns 49,889 shares of the company’s stock valued at $42,596,000 after acquiring an additional 793 shares in the last quarter. Bingham Private Wealth LLC lifted its stake in McKesson by 4.2% in the 3rd quarter. Bingham Private Wealth LLC now owns 577 shares of the company’s stock worth $493,000 after purchasing an additional 23 shares in the last quarter. Maryland State Retirement & Pension System lifted its stake in McKesson by 7.9% in the 3rd quarter. Maryland State Retirement & Pension System now owns 7,190 shares of the company’s stock worth $6,139,000 after purchasing an additional 527 shares in the last quarter. Ritholtz Wealth Management lifted its stake in McKesson by 6.3% in the 3rd quarter. Ritholtz Wealth Management now owns 14,918 shares of the company’s stock worth $12,737,000 after purchasing an additional 887 shares in the last quarter. Finally, UNIVEST FINANCIAL Corp boosted its holdings in shares of McKesson by 4.3% during the 3rd quarter. UNIVEST FINANCIAL Corp now owns 675 shares of the company’s stock valued at $576,000 after purchasing an additional 28 shares during the last quarter. 85.07% of the stock is owned by hedge funds and other institutional investors.

McKesson News Summary

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: For fiscal Q2 2027, McKesson reported adjusted EPS of $11.68 versus analyst estimates near $10.70, while revenue of about $111 billion also topped expectations and grew roughly 7.5% year over year. MCK Q2 Earnings Beat Estimates on Specialty Growth, Outlook Raised
• Positive Sentiment: Management raised fiscal 2027 adjusted EPS guidance to $45.60–$46.40, citing specialty-drug demand, higher prescription volumes, operating improvements and GLP-1 momentum. The company also completed its $2.25 billion Precision Medicine Group acquisition, expanding its healthcare services footprint. Earnings Call Highlights: Raised Guidance, GLP-1 Momentum
• Positive Sentiment: Several firms raised targets, including TD Cowen, Leerink Partners and Evercore ISI to $1,200; Deutsche Bank raised its target to $1,120. RBC also praised McKesson’s execution, and a Seeking Alpha analysis described normalized earnings as supporting an attractive valuation. TD Cowen Raises Price Target
• Neutral Sentiment: EVP Francisco Fraga sold 600 shares under a pre-arranged trading plan to cover tax withholding on vested equity awards; he retained 5,064 shares, making the transaction less indicative of a change in business outlook. SEC Filing
• Negative Sentiment: RBC’s “sector perform” rating came with a $965 target—below the recent share price—suggesting limited upside in that firm’s view despite its target increase. RBC on McKesson’s Execution

McKesson Company Profile

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and medical products to pharmacies, hospitals, health systems, physicians and other healthcare providers. The company also provides technology, data and business solutions designed to support prescription management, pharmacy operations and patient care.

McKesson’s principal activities include pharmaceutical distribution, medical-surgical supply distribution, specialty pharmaceutical services and oncology care support.